Extracorporeal myocardial shockwave therapy; a precious blast for refractory angina patients.
Refractory Angina Pectoris (RAP) dramatically affects patients' life quality and medical costs. External Shockwave Myocardial Revascularization (ESMR) improves the cardiac blood flow thanks to its pro-angiogenetic action on ischaemic tissues. We hereby describe our experience of ESMR in RAP patients. This is a retrospective study encompassing all patients referred to OSR for RAP treatment. Efficacy of ESMR was assessed considering the difference between pre and post therapy data in SAQ score and CCS, stress test performance, 24h ECG monitoring, NT-proBNP and echocardiographic measures. From a total of 97 patients with RAP, 19 patients underwent ESMR, whereas 4 were considered as control group. After the end of the treatment, ESWT group showed a significant improvement in CCS class (-1.32±0.58; p<0.001) and in each of the five variables of the SAQ score (p<0.05). Patients also improved their exercise duration (50,74±29.40 seconds; p<0,001) and double product (1340,53±1321,77; p<0,001) and reduced the number of daily ST segment depression (-1,16±1,01; p<0,01). Ejection Fraction (2,05±1,84%; p<0,01) and Cardiac Output (0,20±0,28L, p<0,01) improved too. No changes were documented in the control group. ESMR is an efficient therapy for refractory angina capable to improve both symptoms and instrumental tests.